Relypsa, Inc. has entered into a multi-year commercial manufacturing and supply agreement with DSM Fine Chemicals for the API for patiromer, the company’s novel polymer in development for the treatment of hyperkalemia. DSM Fine Chemicals is a business unit of the newly formed DPx Holding B.V., which also owns Patheon and Banner Life Sciences.   In addition to DSM, Relypsa also has an agreement with Lanxess Corp. for the supply of API. Both companies manufactured and supplied API for the cl...